department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

ASTRAZENECA PLC ($AZN) · pipeline · pharmadog

← back to ASTRAZENECA PLC

Pipeline · $AZN

38 products

MarketedCALQUENCECALQUENCE (ACALABRUTINIB)MarketedcapivasertibTruqap (capivasertib)Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)Marketeddapagliflozin propanediolFarxiga (dapagliflozin propanediol)Myocardial Infarction Marketedeplontersen sodiumWainua (eplontersen sodium)Familial Amyloid Cardiomyopathy Marketedosimertinib mesylateTagrisso (osimertinib mesylate)Non-Small Cell Lung Cancer Phase 3(balcinrenone + dapagliflozin)(balcinrenone + dapagliflozin)Congestive Heart Failure (Heart Failure)Phase 3AZD-1390Recurrent Glioblastoma Multiforme (GBM)Phase 3anifrolumabSaphnelo (anifrolumab-fnia)Idiopathic Inflammatory Myopathy (IIM)Phase 3cediranib maleateEpithelial Ovarian Cancer Phase 3sonesitatug vedotinAdenocarcinoma Of The Gastroesophageal Junction Phase 3tozorakimabAcute Respiratory Failure Phase 3tremelimumabImjudo (tremelimumab-actl)Small-Cell Lung Cancer Phase 2AZD-0292Bronchiectasis Phase 2AZD-5148Clostridioides difficile Infections (Clostridium difficile Associated Disease)Phase 2AZD-5863Adenocarcinoma Of The Gastroesophageal Junction Phase 2AZD-7760Staphylococcus aureus Infections Phase 2JAB-23E73Metastatic Colorectal Cancer Phase 2MEDI-0457Oropharyngeal Cancer Phase 2TBA-7371Pulmonary Tuberculosis Phase 2durvalumab + IPH-5201Non-Small Cell Lung Cancer Phase 2elecoglipronType 2 Diabetes Phase 2palacaparibpalacaparib [INN]Malignant Glioma Phase 2saracatinib difumarateIdiopathic Pulmonary Fibrosis Phase 2savolitinibNon-Small Cell Lung Cancer Phase 2surovatamigsurovatamig [INN]B-Cell Non-Hodgkin Lymphoma Phase 2vemzatatug vedotinvemzatatug vedotin[INN]Refractory Multiple Myeloma Phase 1AZD-8965Idiopathic Pulmonary Fibrosis PreclinicalTRL-3D3Respiratory Syncytial Virus (RSV) Infections pre_registration(budesonide + formoterol fumarate + glycopyrrolate)Breztri ((budesonide + formoterol fumarate + glycopyrrolate))Asthma BEYFORTUSBEYFORTUS (NIRSEVIMAB-ALIP)1 INDICATIONS AND USAGE BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. BEYFORTUS is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. ( 1 ) Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. ( 1 )

← prevpage 1 of 2next →